Install
FDA and drugs
Drug approvals, trials and the drugmakers.
The latest
-
We bought what was sold as an experimental weight loss drug. Then we tested it.CBS News is a trusted source for the latest in politics, U.S. and world news. The network is home to award-winning broadcasts CBS Mornings, CBS Evening News, 60 Minutes, CBS Sunday Morning, 48 Hours and Face the Nation. We tested vials… -
Is my GLP-1 safe? What to know about FDA's crackdown on copycat drugsCheaper copycat versions of the popular weight-loss drugs Wegovy and Zepbound are still being marketed to consumers. The thriving market for "compounded" GLP-1 medications persists despite warnings from federal drug regulators, a recall… -
This company can get you a GLP-1 weight loss medication within 48 hours — for under $100It’s 2026 — and yes, you can have your GLP-1 delivered straight to your front door. The use of popular GLP-1 medications, such as Wegovy, Zepbound, Ozempic and Mounjaro, has skyrocketed in recent years. According to Gallup, roughly 28… -
Quantum BioPharma (NASDAQ: QNTM) Featured in Men’s Fitness Article Examining Unbuzzd Clinical Trial ResultsUSA Today Quantum BioPharma (NASDAQ: QNTM) Featured in Men’s Fitness Article Examining Unbuzzd Clinical Trial Results Quantum BioPharma (NASDAQ: QNTM) was featured in a Men’s Fitness article by Lakshan Weeraratne examining clinical trial… -
Oyster Recall Map Shows States Impacted by Salmonella OutbreakOct 20, 2026 at 07:09 AM EDT An outbreak of Salmonella across 12 states is under investigation by the Centers for Disease Control and Prevention (CDC), marking the latest multistate foodborne illness outbreak this year. The CDC says the… -
Novo's next-generation obesity drug shows 25% weight loss in women in late-stage analysisNovo on Tuesday said its next-generation obesity drug, CagriSema, showed 25% weight loss on average among adult women in a new analysis conducted after a late-stage trial. The Danish company said further work is needed to confirm the… -
Five-Year Consortium Plans Bioengineered Hearts for ChildrenA five-year, up-to-$29.6 million research consortium will develop living cardiac tissues for infants and young children with congenital heart disease and progress through laboratory and large-animal studies, but it has not yet produced… -
Single-arm trial finds preliminary hetrombopag activity in gynecologic cancerA small single-arm trial found preliminary platelet-recovery activity and no serious adverse events among 37 Chinese patients with gynecologic malignancies receiving concurrent chemoradiotherapy. A single-arm exploratory trial found that… -
ASHG: Population Screening Drives Action in Study of 500K+ASHG: Population Screening for CDC Tier 1 Conditions Drives Health Actions in Study of Over 500K People GenomeWeb ASHG: Population Screening for CDC Tier 1 Conditions Drives Health Actions in Study of 500K+ People -
Supplement Expiration Dates: California’s AB 2779 and What Comes NextTodd Harrison, co-chair of the FDA practice group at Venable LLP, explains how California’s AB 2779 changes date-labeling requirements for supplements, why stability testing matters, and how companies can navigate evolving state rules… - Genome Medicine Sweden Starts PacBio Clinical Sequencing for DxGenome Medicine Sweden Introduces PacBio Long-Read Sequencing for Rare Disease Dx GenomeWeb Genome Medicine Sweden Introduces PacBio Long-Read Sequencing for Rare Disease Dx
-
Retrospective study links postoperative recurrence to longer survival with osimertinibA six-center retrospective study of 275 osimertinib-treated patients associated postoperative recurrence with longer progression-free and overall survival than de novo stage IV EGFR-mutant lung adenocarcinoma. Patients with EGFR-mutant… -
Navigating Supplement Ingredients and Claims Regulations in Europe, the US, and CanadaNutritional Outlook delivers news for manufacturers of dietary supplements, healthy foods, and nutritional beverages, from research to regulatory updates. Three very different regulatory rulebooks See how ingredient eligibility and claims… -
FDA accepts new drug application for UGN-103 in recurrent LG-IR-NMIBCThe FDA has accepted for review a new drug application (NDA) seeking approval of UGN-103 (mitomycin) for intravesical solution for recurrent low-grade intermediate-risk non–muscle invasive bladder cancer (LG-IR-NMIBC).1 The agency issued a… -
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCCTHE COUNTDOWN IS ON The guidelines incorporate cosibelimab for locally advanced cutaneous squamous cell carcinoma after favorable results in the CK-301-101 trial. The National Comprehensive Cancer Network (NCCN) has added cosibelimab-ipdl… -
ECOG-ACRIN opens trial testing ivonescimab for aggressive bile duct cancerEA2251 will evaluate ivonescimab combined with gemcitabine and cisplatin chemotherapy (GemCis) compared with pembrolizumab or durvalumab combined with GemCis in a U.S. population. Overall survival is the primary endpoint. The reported… -
Nearly Two in Three Eosinophilic Esophagitis Patients on Tezspire Reached Tissue Remission After One Year of TreatmentFor patients, the question that matters most is swallowing. Eosinophilic esophagitis, or EoE, can make solid food feel stuck in the throat and turn ordinary meals into a source of anxiety. The trial also found improvements in swallowing… -
Study Finds Geographic Gaps in TNBC Trial Access Persist Across USTHE COUNTDOWN IS ON New analysis reveals major gaps in US TNBC trial access, leaving rural and minority communities with fewer treatment options and research opportunities. An analysis published in Breast Cancer Research and Treatment… -
AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative NeoplasmsFinancialContent - AN2 Therapeutics to Present Phase 2 Design for Epetraborole in Polycythemia Vera at the 18th International Congress on Myeloproliferative Neoplasms FinancialContent (Nasdaq: ANTX), a clinical stage biopharmaceutical… -
Sierra Nevada Cheese Recalled Every Graziers Raw Milk Cheese for E. coli O26 on September 24. Twenty-Seven Days Later, FDA’s Enforcement Record Lists One Product, 1,373 Pounds and Thirteen States, Washington Among Them.The company’s notice covers ten products and names no lot code. The enforcement record covers one product and names thirteen. The one product on the record is not the product linked to the illnesses. The distribution list leaves out five…
Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Conservative, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Conservative index; prices of stocks, rates and coins from 4Conservative Finance. Nothing here is betting, financial or investment advice. Terms of use.